Monday, May 20, 2019 9:02:56 PM
It’s hard to understand how we are making less money after the US clearances than we were before internationally.
While many companies get in trouble for inflating their quarterly numbers by cooking the books, it’s almost like the opposite is happening here.
Hard to understand how the numbers could be this bad in the midst of CVS rollout and modest expansion.
I’m not going anywhere, but I’m at a loss to explain how this company’s doing so poorly.
The buck stops at the CEO, President and Chairman of the Board - our Andy Whelan.
Bring back Ed Staelin for god sakes or sell this company to the highest bidder and end our misery.
It’s almost comical now. I’d laugh if I hadn’t poured thousands into it.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM